Disease-specific metabolic and, most recently, epigenetic signatures are established to initiate genetic testing or validate genetic findings. GENOMIT aims to facilitate and prompt clinical trials for improved disease management approaches by establishing specific outcome measures and identifying novel therapeutic targets. Each new biomarker will also provide novel insights into the pathophysiology of the underlying disorder.